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Abstract
There has been a worldwide increase in autism cases in the past few decades, but the cause of it is unclear. It has
been suggested that vaccines may be contributing to the rise in autism rates. One claim is that the MMR vaccine can
cause intestinal inflammation that may lead non-permeable peptides to be transferred to the brain where it will affect
neurodevelopment. This may lead to autism with symptoms of developmental regression and gastrointestinal problems.
Another major hypothesis that has received much attention is that a mercury-containing compound, thimerosal, found
in many vaccines, can have toxic effects on the central nervous system. By retrieving studies from databases such as
Ebsco, Proquest, and Pubmed found in the Touro College Library, this review investigates if there is any truth to these
claims. No evidence of a direct link between vaccines and an increase in autism cases have been found.
Introduction

Methods

There has been a worldwide increase in autism cases in the past
few decades, but the cause of it is unclear. It has been suggested
that vaccines may be contributing to the rise in autism rates.
One claim is that the MMR vaccine can cause intestinal inflammation that may lead non-permeable peptides to be transferred
to the brain where it will affect neurodevelopment. This may
lead to autism with symptoms of developmental regression
and gastrointestinal problems. Another major hypothesis that
has received much attention is that a mercury-containing compound, thimerosal, found in many vaccines, can have toxic effects
on the central nervous system. By retrieving studies from databases such as Ebsco, Proquest, and Pubmed found in the Touro
College Library, this review investigates if there is any truth to
these claims. No evidence of a direct link between vaccines and
an increase in autism cases have been found.

Information and research was obtained through databases such
as Ebsco, Proquest, and Pubmed. Access was provided by the
Touro College Library. Google Scholar was also used to find
research articles. Keywords like vaccines, autism, and thimerosal
were used to search for relevant material. In addition, references in these articles were retrieved and used as additional
sources for further research.

Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that impairs a child’s ability to interact and communicate
with others. It is commonly associated with certain behaviors
such as difficulty making conversation, delayed language acquisition, and poor motor skills. Autism seems to originate from
very early brain development. The most obvious symptoms of
the disorder, however, usually begin to show between the ages
of 2 and 3. (Autism Speaks, 2016) Autism diagnoses have greatly increased in the past few decades. According to statistics
from the U.S. Centers for Disease Control and Prevention, the
prevalence of autism in 1000 children was approximately 6.7 in
the year 2000 and 14.7 in 2010, a significant increase. (Data &
Statistics, 2015).The cause for this dramatic increase is unknown
and has been the subject of much investigation. It is believed
that genes play a role in an increasing risk for autism (Mascarelli,
2010). However, environmental factors play a part in most cases
of autism too. There has been a growing concern of a possible
link between vaccines and autism. Two separate theories have
been proposed over the years. One is that the Measles-MumpsRubella (MMR) vaccine causes autism. The other is that thimerosal, a mercury containing preservative found in many vaccines
can lead to damage in the brain. Researchers have sought to
discover if there is any truth to these claims.
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Discussion
MMR Vaccine
In 1968 a link was suggested between the Mumps, Measles, and
Rubella (MMR) vaccine and the onset of ASD. Unusual bowel
symptoms were described among 12 children who showed developmental regression like losing acquired skills despite previous normal progress. Eight out of the twelve children who had
gastrointestinal signs had reported their first symptoms of autism within a month of receiving the MMR immunization. It was
concluded that the MMR vaccine caused intestinal inflammation
allowing usually non-permeable peptides to be translocated to
the bloodstream and ultimately to the brain, where they affected development. (Wakefield, et al. 1998) Although the sample
was small with only a dozen children and the results were never
replicated, the study received lots of attention from the public, and served as the foundation for much controversy in the
years to come. Parent’s anecdotes of their own personal experiences were enough for many to keep this alive. As a result,
many refused to vaccinate their children worrying about their
safety, and outbreaks of vaccine preventable diseases began reappearing in certain areas. The MMR-autism controversy was
responsible for a significant decrease in immunizations following
that year. The MMR immunization rates in the United Kingdom
dropped from 90% in 1988, when they were first introduced,
to 80% in 2004, after the article had been read by the public.
(Kolodziejski, 2014)

Possible Developmental Regression and
Gastrointestinal Symptoms Associated with MMR
Whether MMR is really associated with autism has been under
constant debate. There have been many studies done to see if
the link exists. Fombonne and Chakrabarti (2001) tested out
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the hypothesis that a form of autism existed involving developmental regression and gastrointestinal symptoms caused by
the MMR vaccine. It was proposed that if one or more of the
following predictions were proved by the data collected, the hypothesis could be validated. The first prediction was that childhood disintegrative disorder (CDD) had become more common. Another is that the average age of first parental concern
in autistic children in those who received the MMR vaccine is
closer to the mean age of immunization than in those who were
not vaccinated with MMR. The third prediction was that developmental regression in those who are vaccinated with MMR
had become more frequent. If the age of onset of autism with
regression is closer to MMR-vaccination as opposed to those
who did have autism without regression, it could also prove
that MMR could have caused autism. Another prediction is that
those with regressive autism have different symptoms. Finally,
those with regressive autism would have gastrointestinal signs
and/or inflammatory bowel disorder.
Three samples, 1 epidemiological (n=96) and 2 clinical samples, a pre-MMR (n=68) and a post-MMR (n=98) were used
to gather information. In order to assess age of first onset of
autistic signs, the parents were asked how old their child was
when they first became concerned with his/her development.
Regression was noted when a loss of skill, such as language
was confirmed based on certain criteria. Assessment of bowel
symptoms was done by retrieving data from both the parents
and pediatrician.
The first prediction of childhood disintegrative disorder (CDD)
increasing was not supported by the data as only one boy met
the criterion for CDD, which seems likely to have originated
from brain pathology before the MMR immunization was even
given. In this epidemiological sample where nearly all the children were vaccinated, it can be assumed that CDD is not increased with vaccine exposure. Second, there was no difference
in age of first parental concern in two of the samples exposed to
MMR (19.3 and 19.2) compared to the pre-MMR clinical sample
(19.5). Third, the rate of regression for the post-MMR sample
(15.6%) was lower than the rate in the pre-MMR sample (18.4%).
This rules out MMR-induced regressive autism as a cause for
the dramatic increase in autism cases. In the epidemiologic
sample, 18.8% had gastrointestinal symptoms. Constipation was
the most common symptom (9.4%), and no inflammatory bowel
disorder was reported. Only 2.1% of the sample experienced
both developmental regression and gastrointestinal symptoms,
a rate which shows no association between the two. None of
the 6 predictions were supported in this study, and no evidence
was found to show a distinct syndrome of MMR-induced autism.
(Fombonne E, Chakrabarti S, 2001).

Measles Virus RNA in Patients with Autism
There are studies that have reported Measles Virus (MV) RNA
in bowel biopsies in autistic children, showing a possible link
between intestinal inflammation and the measles virus. A study
done by Kawashima et al (2000), examined children with gastrointestinal problems to see if they have the measles virus and if
they did, if it derived from wild strains or vaccine strains. Eight
of the patients had Crohn’s disease, 3 had ulcerative colitis, and
9 had autistic enterocolitis. One of the patients with Crohn’s
disease, 1 with ulcerative colitis, and 3 of 9 with autism were
positive for the virus, while the controls were all negative. The
measles virus found in the patient with Crohn’s disease proved
to have characteristics of wild-strain virus, while the one with
ulcerative colitis and in the autistic patients had vaccine strains.
A study including 125 autistic children and 92 control children.
MMR antibodies were first measured by ELISA in sera of 24
randomly selected autistic children, 16 normal children, and 14
children with other developmental problems. Autistic children
had a higher number of MMR antibodies compared to the other
children. Soon after all of the 217 children were checked for
MMR antibodies by immunoblotting assay for serum screening.
They found that 75 (n=125) autistic children’s sera were positive
for an unusual MMR antibody, whereas none of the control sera
had the antibody. A protein band was detected in the antibody
which was immunopositive for measles HA protein but not for
measles nucleoprotein and rubella or mumps viral proteins. The
results showed that autistic sera detected measles HA protein
in the MMR antibody. It is suggested that an inappropriate antibody response to MMR might be related to the development of
autism. (Singh, et al, 2002)
However, despite those few studies, many studies have been
done that disprove the link between autism and MMR including
a few that failed to detect MV-RNA in cases of autism. A case
control study tested for the presence of measles virus (MV)
RNA in bowel tissue in children with ASD. The purpose was to
see if those with GI disturbances and autism are more likely to
have MV RNA in their bowel tissue than those with GI symptoms but no autism. This can determine if MMR is linked to this
type of autism. The ileal and cecal tissues of 25 children with GI
disturbances and autism and 13 children with GI disturbances
but no autism were analyzed for MV RNA in 3 different laboratories. The timing of the autistic and gastrointestinal symptoms
in respect to MMR immunization was also documented. The
results showed no difference in MV RNA findings in the case
group and the control group. The timing of the vaccine in regards to the GI symptoms and autism onset were inconsistent
with the theory that MMR triggers either the GI symptoms or
autism. (Hornig, et al, 2008)
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A 14 year prospective study reviewed the number of vaccines
that were given from the time The National Board of Health
and National Public Health Institute launched their MMR vaccination program in 1982 till the year 1996. 3 million vaccines
were given during that period of time and 31 cases of gastrointestinal symptoms were reported after vaccination, ranging
from 20 hours to 15 days. Fifty five percent (n=17) had symptoms of diarrhea and vomiting, 23% (n=7) had gingivostomatitis,
16% (n=5) had vomiting only, and (n=2) had abdominal pains.
The symptoms usually lasted about a week. None of the children developed autism. In this study, no association was found
between MMR and pervasive developmental disorder or inflammatory bowel disease. (Peltola et al, 1998)

Figure 1

Epidemiological Studies
Numerous epidemiologic studies have been done to see if there
is an association between MMR and autism. Taylor, et al (1999)
did a chart review of cases of autism diagnosed in a region in
England, in children born between 1979-1992. They identified
498 cases of ASDs in the population, of which only 293 could
be confirmed according to ICD-10 criteria. They analyzed the
data in different ways to test if autism was related to the MMR
vaccination. Data they collected included the age at which the
children were diagnosed, the age of first parental concern, and
age when regression became obvious. The trend of autism
was examined to see whether or not there had been a sudden
step-up in autism diagnoses in children who received the MMR
vaccine after it was introduced in England in 1988. They found
that the prevalence rates of autism began an exponential rise
starting with children born a couple of years before the introduction of the MMR vaccine, and that there had been no sudden
step-up after 1988. They concluded that this refuted a temporal
relationship.
A study done in California collected data regarding MMR coverage rates and age at the time of immunization for children
born between the years 1980-1994 from school immunization
records in California Kindergartens. The number of cases of
autism diagnosed during those years were retrieved from the
California Department of Developmental Services where they
were enrolled. The results did not show a correlation between
rates of autism and number of immunizations given. As can
be seen by Figure 1, autism cases increased from 44 cases per
100,000 live births in the 1980 cohort to 208 cases per 100,000
live birth in the 1994 cohort, a 393% increase. In contrast, MMR
immunization rates by the age of 24 months increased from
72% to 82%, only a 10% increase. Since the rate of increasing
autism cases does not compare with the only small rise in MMR
coverage, a correlation was not observed between the two.
(Dales, et al, 2001)
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Percentage of Children Receiving Measles-Mumps-Rubella (MMR)
Immunization in Second Year of Life and Caseload of Children With
Autism, by Year of Birth, California, 1980-1994 (Dales, et al, 2001)
A population study was done in Japan by Honda, et al (2005). It
examined incidence of ASD in children born from 1988-1996.
Japan’s MMR immunization program was launched in 1989 but
ended in 1993, due to suspected side effects of the mumps vaccine. This allowed for an opportunity to research the effect
of removing the MMR vaccine which was believed to cause a
rise in autism. If it was really the cause of the increased autism
caseloads when it was introduced, autism would drop after the
risk factor (MMR vaccine) was withdrawn. All children who had
been diagnosed with ASD were selected from a patient list of
the YRC Developmental Psychiatry Unit, which offers diagnostic
and intervention services to all those with ASD. The annual
trends for both typical autism and all other categories of ASD
were examined. According to the statistics, MMR vaccination
rates were 69.8%, 42.9%, 33.6%, 24.0%, and 1.8% respectively
in the years 1989-1993. As can be seen by this data, the rate
decreased significantly during these years, with only a bare minimum of 1.8% of children vaccinated with MMR in the year 1993.
The annual trends of ASD were compiled for the years 19881996. The ASD incidence rates ranged from 47.6 per 10000 in
1988 to 117.2 per 10000 in those that were born in 1996. The
rate of autism incidences continued to rise even after the MMR
vaccination program was terminated. This provides evidence
that it is highly unlikely that MMR is linked to greater autism
incidences. (Table 1) (Honda, et al, 2005)
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Table 1

Thimerosal
Since the 1930s, thimerosal, a mercury-containing preservative
has been used in many biological and drug products, including
multi-dose vaccines, to prevent bacterial and fungal contamination
Thimerosal is not found in live vaccines, such as MMR because of
the damaging interaction they can have with the active substance.
Before 1991, diphtheria-tetanus-pertussis (DTaP) vaccination was
the only common vaccine that contained thimerosal. Recently
though, more vaccines have been introduced that consist of thimerosal like Hepatitis B and HIB. (Nelson, Bauman, 2003) Too
much mercury can have toxic effects especially in little children,
where the brain is still developing. As can be seen by Table 2,
the FDA estimated that 6-month old babies could have received
doses of mercury as high as 187.5 µg in their vaccines and 2 year
olds as much as 237.5 µg. (Freed, et al, 2002)

Table 2

Because of the increasing amount of this chemical that babies
were being exposed to, there was a growing concern that the
ethylmercury which is found in thimerosal can cause brain damage and contribute to autism. Fearing this, the FDA removed
thimerosal from all vaccines in 1999 even though direct evidence of harm was not found. Since not much was not known
about ethylmercury at that point in time, assumptions were
made based on knowledge of methylmercury. Methylmercury
was known to have toxic effects and many assumed that

ethylmercury has similar consequences.
Since ethylmercury had not been extensively studied, researchers began to experiment with ethylmercury to see if it
can really have those damaging effects in
vaccines. (Straton, 2001)
Research was done by analyzing the
VAERS database, a database maintained by
the CDC which holds a record of all adverse reactions. The VAERS database was
used to compare the neurodevelopmental
disorders that were found following the administration of thimerosal-containing DTaP vaccines in contrast to thimerosal-free
DTaP vaccines. A close linear correlation was found between increasing mercury due to thimerosal vaccines and an increase in
the odds ratio of neurodevelopmental disorders. According to
the results in the baseline year of 1984, the odds ratio of autism
increased by 0.029 per mg of mercury, personality disorders by
0.012 per mg of mercury, and mental retardation by 0.048 per
mg of mercury. The total odds of developing autism increased in
those immunized with thimerosal-containing vaccines vs those
who received thimerosal-free vaccines. This study showed that
more research had to be done to see if there is indeed a correlation between mercury levels and higher risks of autism and
other developmental disorders. (Geier et al, 2003)
A study done used hair and urine analysis to detect heavy metal
exposure in those with autism compared to those who did not
have autism. It consisted of 25 autistic children and 25 controls. Metal testing was performed via ICP-MS spectroscopy
utilizing cell technique to detect levels of different metals in the
hair. The mean mercury level in the hair of autistic children was
0.47±0.42 while the levels in the control children was a lower
mean of 0.30±0.3. A similar observation was found of the mercury levels in the urine of autistic children compared to control
children, with means of 2.48±2, and 1.10±0, respectively. These
results seem to show an association between higher levels of
mercury in those with autism. Limitations in the amount of
mercury they ingest seems to be important for the safety of
these children. However, a larger sample size should be studied
on in order to validate these findings. (Blaurock-Busch, 2011)
A study was done by Pichichero et al, (2002) to measure the
concentration of mercury found in infants’ stool, blood, and
urine after they received vaccines. If high levels were found, it
would show that thimerosal can be potentially harmful in vaccines. In this experiment, 40 infants who were 6 months or
younger received thimerosal containing vaccines while 21 controls received thimerosal free vaccines. Samples of the infants’
stool, blood, and urine were obtained 3-28 days after and were
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tested for mercury levels. Blood samples contained low levels
of mercury with a range of 4.50-20.55 nmol/L. Fourteen out of
15 controls did not have quantifiable levels of mercury. Those
with the highest levels of mercury were infants who were measured soon after they were vaccinated. There was no mercury
found in urine samples, besides for one of the 2-month olds
and three of the 6-month olds who had received thimerosal
in their vaccines. The highest amount of mercury in the urine
was 6.45 nmol/L. No mercury was found in any of the control
infants. Detectable amounts of mercury were found in stool
samples in those who were exposed to thimerosal containing
vaccines. Those who did received thimerosal free vaccines were
not measured for mercury levels in their stool. (Table 3)

Figure 2

Table 3
can accumulate and get converted to inorganic mercury which
can cause neurodevelopmental damage. Ethylmercury, however,
which is found in thimerosal is rapidly eliminated through the
stool which prevents toxicity from accumulating that could be
detrimental to parts of the body including the brain. (Pichichero,
et al, 2002)

To determine if dietary intake could contribute to mercury
levels in the stool, samples were obtained from 9 infants who
were age-matched to those who received thimerosal containing
vaccines but were not exposed to thimerosal themselves. The
mean levels of mercury in these samples was 22 ng/g which
was considerably lower than those exposed to thimerosal. Out
of all these samples, however, no concentration exceeded 29
nmol/L which is known to be an accepted safe value. The results
did show an increased amount of mercury in those who were
vaccinated compared to those who did not receive thimerosal,
but the quantity was still below the harmful level. Before the
samples were measured, a prediction model was made of the
expected measurements of mercury corresponding to the possible half-life days ranging from 1-45. The best estimate of the
half-life of ethylmercury would be the difference between the
predicted value and the observed value.
The concentration of mercury in the blood not long after vaccination suggests that the half-life of ethylmercury is not nearly
as long as the half-life of methylmercury. As we can see from
Figure 2, the estimated half-life for ethylmercury was 7 days.
This contrasts with the half-life of around 40-50 days in methylmercury. The long half-life of methylmercury can allow the
organic-mercury to cross over the blood brain barrier where it
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Since creating controlled experiments is not possible in an existing vaccination program, determining if there is an association
between thimerosal and autism is not so simple. Several epidemiological studies have been done to see if there is a causal
relationship between receiving thimerosal containing vaccines
and an increase in autism cases. A population cohort study of
children in Denmark who were born in the years 1990-1996
was done to compare children who received thimerosal in their
vaccines and those who did not. Doses that were administered before 1992 were considered to be vaccines containing
thimerosal and those doses given after 1992 were thimerosal
free vaccines. Information regarding vaccine administrations
was obtained from the Danish Board of Health and data regarding autism diagnoses was retrieved from the Danish Psychiatric
Central Register. Follow ups were done from one year of age
till the year 2000 to see if there would be possible cases of autism disorders in those children. During these years, 440 cases
of autism and 787 cases of other autistic-spectrum disorders
were diagnosed among those children (table 4).

Table 4
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We can see from the results shown in table 4, that when comparing those who received at least one dose of thimerosal-containing vaccine and those who only received thimerosal-free
vaccinations there was a rate ratio of 0.85% for autism and
1.12% for other autistic spectrum disorders. Also, there was
no association between a higher dose of thimerosal-containing vaccine and a higher rate of autism disorders. The increase
in rate ratio per 25 ug of mercury was 0.98% in autism and
1.03% in other autistic spectrum disorders. In order to rule out
the possibility that some thimerosal-containing vaccines were
administered soon after 1992, the vaccinations between June
and December of 1992 were omitted from the data and similar
results were found. This study showed no association between
thimerosal intake and increased autism rates. (Hviid, et al, 2003)
In the United Kingdom, the only thimerosal containing vaccines
that have been administered in the past few decades is DTaP
and DT. The total amount of thimerosal per dose in these vaccines is 50 ug (25 ug of ethylmercury). In the United Kingdom,
the schedule for vaccination called for 3 doses by the age of 4
months, totaling 150 ug of thimerosal at that age. Data regarding
date of birth and vaccination dates were obtained for 109,863
children who were born from 1988 to 1997. Some children
were excluded from the study including those who had certain
medical conditions before the age of 6 months and those who
had received the Hep B or flu vaccination before 6 months of
age. Hg exposure was calculated based on the number of vaccine doses the children received. A number of developmental
disorders were investigated and the number of cases diagnosed,
the mean age of diagnoses, and the percentage that was male
was assessed. When these children were linked to the dates of
their vaccination and any of the neurodevelopmental disorders
they had, no evidence of increasing neurodevelopmental disorder rate was found with an increasing dose of ethylmercury.
The only disorder that showed a possible link to thimerosal was
tics, which had a hazard rate of 1.50 in 4 months of age. The rest
of the disorders had a Hazard rate close to 1, showing no link to
thimerosal. (Andrews, et al, 2004)
Another study was done in Sweden and Denmark to compare
the prevalence of autism cases with the exposure of thimerosal-containing vaccines during the 1980s and 1990s. Data regarding vaccine coverage and autism cases were collected in
these countries. The total amount of ethylmercury exposure
was calculated by multiplying the amount of thimerosal in vaccines by the number of vaccines with thimerosal administered
during that time period. The rate of autism was calculated by dividing the total number of autism cases diagnosed in those years
by the number of person-years accumulated during those years.
As shown in figure 3a, the incidences of autism in Sweden began

Figure 3a

Figure 3b

to rise in the year 1985 to a rate of around 6 per 100,000
person-years and peaked in the year 1993 to a rate of 9.2 per
100,000 person-years. The coverage of thimerosal-containing
vaccines, however, have remained steady over most of those
years, decreasing over time and eventually being completely
removed in 1993. A similar explanation goes for Denmark,
shown in figure 3b. Thimerosal-containing vaccination coverage
remained constant throughout the years 1981-1991 and ended
in 1992, but autism rates continued to increase sharply in the
years after that. We can see from these studies that the rise of
autism needs a better explanation than the exposure of thimerosal to children.

Conclusion
From the studies that have been done so far, no evidence
has been found to show a link between vaccines and autism.
Increasing autism rates need to have another explanation. It
has been suggested that the broadening of the diagnosis, and the
greater awareness of autism and other ASDs have contributed
to more diagnoses of autism. The claim that MMR is associated
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with a regressive form of autism has been proven to be highly
unlikely. The fact that MMR vaccination withdrawal did not lead
to a decrease in autism cases indicated that there is not any correlation between the two.The concern that thimerosal-containing vaccines cause autism has also not been validated. However,
despite the shorter half-life and less damage that ethylmercury
can have in comparison to other mercury compounds like
methylmercury, the current literature does not rule out a role
for thimerosal in neurodevelopmental damage other than autism to children. Therefore, it is best that thimerosal continue
to remain excluded from vaccines.

References

Autism Speaks. What Is Autism? Available at: https://www.
autismspeaks.org/what-autism. Accessed 2016.
Data & Statistics. Centers for Disease Control and Prevention
2015. Available at: http://www.cdc.gov/ncbddd/autism/data.html.
Accessed 2016.
Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B.
Thimerosal exposure in infants and developmental disorders:
a retrospective cohort study in the United Kingdom does
not support a causal association. Pediatrics [serial online].
September 2004;114(3):584-591. Available from: MEDLINE,
Ipswich, MA. Accessed January 05, 2016.
Blaurock-Busch E, Amin O, Rabah T. Heavy Metals and Trace
Elements in Hair and Urine of a Sample of Arab Children with
Autistic Spectrum Disorder. Romanian Journal Of Medical
Practice [serial online]. December 2011;6(4):247-257. Available
from: Academic Search Complete, Ipswich, MA. Accessed
January 05, 2016.
Bose-O’Reilly S, McCarty KM, Steckling N, Lettmeier B.
Mercury Exposure and Children’s Health. Current problems
in pediatric and adolescent health care. 2010;40(8):186-215.
doi:10.1016/j.cppeds.2010.07.002.
Dales L, Hammer S, Smith NJ. Time Trends in Autism and
in MMR Immunization Coverage in California. JAMA.
2001;285(9):1183-1185. doi:10.1001/jama.285.9.1183.
Freed G, Andreae M, Cowan A, Katz S.The Process of Public
Policy Formulation:The Case of Thimerosal in Vaccines. Pediatrics
[serial online]. June 2002;109(6):1153. Available from: Academic
Search Complete, Ipswich, MA. Accessed January 05, 2016.
Fombonne E, Chakrabarti S. No evidence for a new variant
of measles-mumps-rubella-induced autism. Pediatrics [serial
online]. October 2001;108(4):E58. Available from: MEDLINE,
Ipswich, MA. Accessed January 05, 2016.
Geier D, Geier M. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatric
Rehabilitation [serial online]. April 2003;6(2):97-102 6p.

180

Available from: CINAHL Plus with Full Text, Ipswich, MA.
Accessed January 05, 2016.
Hornig M, Briese T, Buie T, et al. Lack of Association between
Measles Virus Vaccine and Autism with Enteropathy: A CaseControl Study. Cookson MR, ed. PLoS ONE. 2008;3(9):e3140.
doi:10.1371/journal.pone.0003140.
Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association
Between Thimerosal-Containing Vaccine and Autism. JAMA.
2003;290(13):1763-1766. doi:10.1001/jama.290.13.1763.
Kawashima Hisashi, Mori Takayuki, Kashiwagi Yasuko, Takekuma
Kouji, Hoshika Akinori, Andrew Wakefield. Detection and
Sequencing of Measles Virus from Peripheral Mononuclear
Cells from Patients with Inflammatory Bowel Disease and
Autism. 2000. Available at: http://tested.net/vaccine/measles.pdf.
Accessed 2016.
Kolodziejski L. Harms of Hedging in Scientific Discourse:
Andrew Wakefield and the Origins of the Autism Vaccine
Controversy. Technical Communication Quarterly [serial
online]. July 2014;23(3):165-183. Available from: Education
Research Complete, Ipswich, MA. Accessed January 05, 2016.
Mascarelli, AL. Genes play complicated role in autism:
Scientists just beginning to unravel clues. The Orlando
Sentinal 2010. Retrieved from http://search.proquest.com/
docview/750542895/5C65F9DCB03A48CAPQ/5?accountid=14375
Nelson K, Bauman M. Thimerosal and Autism?. Pediatrics [serial
online]. March 2003;111(3):674-679. Available from: Academic
Search Complete, Ipswich, MA.
Parker S, Schwartz B, Todd J, Pickering L. Thimerosal-Containing
Vaccines and Autistic Spectrum Disorder: A Critical Review of
Published Original Data. Pediatrics [serial online]. September
2004;114(3):793-804. Available from: Academic Search
Complete, Ipswich, MA.
Peltola H, Patja A, Leinikki P,Valle M, Davidkin I, Paunio M. No
evidence for measles, mumps, and rubella vaccine-associated
inflammatory bowel disease or autism in a 14-year prospective study. Lancet [serial online]. May 2, 1998;351(9112):1327.
Available from: Business Source Complete, Ipswich, MA.
Pichichero, M. E., Cernichiari, E., Lopreiato, J., & Treanor, J.
(2002). Mercury concentrations and metabolism in infants
receiving vaccines containing thiomersal: A descriptive study.
The Lancet, 360(9347), 1737-41. Retrieved from http://search.
proquest.com/docview/199082475?accountid=14375
Singh V, Lin S, Newell E, Nelson C. Abnormal Measles-MumpsRubella Antibodies and CNS Autoimmunity in Children with
Autism. Journal Of Biomedical Science [serial online]. July
2002;9(4):359-364. Available from: Academic Search Complete,
Ipswich, MA.

Vaccines and Autism

Stehr-Green P, Tull P, Stellfield M, Mortenson P-B, Simpson D.
Autism and thimerosal-containing vaccines. American Journal
of Preventive Medicine 2003. Available at: http://www.ajpmonline.org/article/s0749-3797(03)00113-2/fulltext.
Stratton K, Gable A, McCormick MC, editors. Immunization
Safety Review: Thimerosal-Containing Vaccines and
Neurodevelopmental Disorders. Washington (DC): National
Academies Press (US); 2001. Institute of Medicine (US)
Immunization Safety Review Committee;Available from: http://
www.ncbi.nlm.nih.gov/books/NBK223724/
Taylor B, Miller E, Waight P, et al. Autism and measles,
mumps, and rubella vaccine: no epidemiological evidence
for a causal association. Lancet [serial online]. June 12,
1999;353(9169):2026-2029. Available from: Business Source
Complete, Ipswich, MA.
Wakefield A, Murch S, Anthony A, et al. RETRACTED:
Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and
pervasive developmental disorder in children. The Lancet
1998:637–641.

181

